337913-25-4

Downstream Products

• 20577-26-8 2-bromonicotinonitrile 
• 189746-21-2 5-chloro-2,6-dimethoxy-4-methyl-8-nitro-quinoline 
• 2622-67-5 1,2-diphenyl-1H-benzoimidazole 
• 34234-03-2 7-cyclohex-1-enyl-azepan-2-one 
• 175712-66-0 1-phenyl-2-(3-chlorophenyl)benzimidazole 
• 54903-11-6 6-propanoyl-3H-1,3-benzoxazol-2-one 
• 22246-12-4 6-methoxy-1,2,3,4-tetrahydro-1-oxoisoquinoline 
• 134814-96-3 2-chloro-4-fluoro-5-nitrophenol methoxymethyl ether 
• 36865-40-4 1-bromo-3-ethoxypropane 
• 180315-60-0 (S)-N-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-oxo-3-phenylpropyl]-1,4-dihydro-pyridine 
• 14525-91-8 6-benzyl-6-phenyl-piperidin-2-one 
• 110931-79-8 5,7-difluoro-1,2,3,4-tetrahydronaphthalen-1-one 
• 115768-94-0 6,7-Dimethoxy-1-[(2-methylthio)phenyl]-3,4-dihydroisoquinoline 
• 97110-52-6 1-phenyl-as-triazino[6,1-a]isoquinolinium-perchlorate 

Relevant academic research and scientific papers

Psoralens for pathogen inactivation

Psoralen compound compositions are synthesized which have primaryamino substitutions on the 3-, 4-, 5-, and 8- positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these psoralens result in the inactivation of pathogens which contain nucleic acid. The compounds show similar activity in test systems to 4'' and 5'' derivatives of psoralen useful for inactivation of pathogens in blood products. In addition to the psoralen compositions, the invention contemplates such inactivating methods using the new psoralens.

Process for the preparation of lamotrigine

The invention provides a process for producing lamotrigine of formula (I): STR1 which process comprises subjecting a compound of formula (II): STR2 wherein R is CN or CONH2, in an organic solvent, to ultra violet or visible radiation and, when R is CN, to heat.

4-(substituted)amino-3-arylpyrrolinone derivatives

The invention relates to new 4-(substituted)amino-3-arylpyrrolinone derivatives of the general formula (I) STR1 in which X, Y, Z, n, B, M, L and A are as defined in the description, to a process and new intermediates for their preparation, and to their us

Novel 3-acyloxymethyl-cephem compounds useful as intermediates for preparing cephalosporin antibiotics

Novel 3-acyloxymethyl-cephem compounds of the formula: STR1 wherein R1 is hydrogen or an acyl group; W is acetonyl, or a group represented by --X--COOH or --X--OH (X is an organic residue) or salts thereof were found to be useful as starting materials for preparing cephalosporins of the formula: STR2 wherein R3 stands for a residue of a nucleophilic compound and R1 has the same meaning as above.